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Abstract
Background: Acute respiratory illnesses (ARIs) during childhood are often caused by respiratory viruses,
result in significant morbidity, and have associated costs for families and society. Despite their ubiquity,
there is a lack of interdisciplinary epidemiologic and economic research that has collected primary impact
data, particularly associated with indirect costs, from families during ARIs in children.
Methods: We conducted a 12-month cohort study in 234 preschool children with impact diary recording
and PCR testing of nose-throat swabs for viruses during an ARI. We used applied values to estimate a
virus-specific mean cost of ARIs.
Results:  Impact diaries were available for 72% (523/725) of community-managed illnesses between
January 2003 and January 2004. The mean cost of ARIs was AU$309 (95% confidence interval $263 to
$354). Influenza illnesses had a mean cost of $904, compared with RSV, $304, the next most expensive
single-virus illness, although confidence intervals overlapped. Mean carer time away from usual activity per
day was two hours for influenza ARIs and between 30 and 45 minutes for all other ARI categories.
Conclusion: From a societal perspective, community-managed ARIs are a significant cost burden on
families and society. The point estimate of the mean cost of community-managed influenza illnesses in
healthy preschool aged children is three times greater than those illnesses caused by RSV and other
respiratory viruses. Indirect costs, particularly carer time away from usual activity, are the key cost drivers
for ARIs in children. The use of parent-collected specimens may enhance ARI surveillance and reduce any
potential Hawthorne effect caused by compliance with study procedures. These findings reinforce the
need for further integrated epidemiologic and economic research of ARIs in children to allow for
comprehensive cost-effectiveness assessments of preventive and therapeutic options.
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Background
Respiratory virus infections are a major cause of morbidity
and healthcare usage in children, resulting in substantial
costs for families and society [1-5]. Given their ubiquity,
there has been surprisingly little research examining the
costs associated with childhood respiratory infections that
has involved collecting primary data from families. Even
for influenza, the most studied of all respiratory viruses,
cost-of-illness and vaccine cost-effectiveness evaluations
in children have tended to rely on assumptions or use ret-
rospectively collected estimates, often from surveys, for
resource utilisation, such as carer time away from work in
seeking healthcare or caring for an ill child [6-9].
There are three pieces of evidence required by those devel-
oping health policy in assessing whether to recommend
or implement a publicly-funded vaccination program, or
any intervention, against respiratory viruses: epidemiol-
ogy of the targeted illness, the efficacy of the intervention,
and the cost-effectiveness of the intervention [10]. All
interventions to prevent or treat infections will be associ-
ated with a cost of implementation, but cost-effectiveness
is determined not only by the cost of the intervention, but
also by costs arising from the illness. Getting these data for
respiratory viruses, particularly information on indirect
costs incurred by families, requires a conjunction of epi-
demiologic and economic research [11].
The prospect of new and improved influenza vaccines
[12], the hope of new vaccines against other respiratory
viruses [13], development of novel therapeutic possibili-
ties [14], and the possible use of nonpharmaceutical inter-
ventions to contain virus transmission [15-18] all
underline the need to more critically weigh the costs and
benefits of prevention and treatment for common respira-
tory tract viruses.
We present here findings from a community-based cohort
study using parent-collected specimens for etiologic
assignment and diary recording of impact data. These data
have been used to calculate virus-specific costs of illness
from a societal perspective, including often neglected
indirect costs.
Methods
The study cohort and acute respiratory illness surveillance
Details of recruitment, composition, and maintenance of
the dynamic study cohort have been published elsewhere
[19]. Ethics approval for the study was given by the Royal
Children's Hospital Ethics in Human Research Commit-
tee, Melbourne, and written informed consent was
obtained from parents before participation.
This dynamic cohort consisted of one healthy child less
than five years of age at time of recruitment from each
study family. Children involved in this study were
recruited from a number of sources. In Victoria, Australia,
maternal and child health nurses (MCHNs) provide sup-
port to families during the early childhood years, particu-
larly on issues to do with general health and vaccination.
Based on a model used by our group for community vac-
cine studies [20], MCHNs from 26 local councils assisted
with recruitment by providing study information to par-
ents of eligible children. Advertising material for the study
was placed in child care and playgroup centers and,
because of proximity, we also used bulletin boards and
staff e-mail lists at the Royal Children's and the Royal
Women's Hospitals in Melbourne. Details about the study
child and household demographics were collected at an
enrolment home visit, including annual gross household
income collected in 2003/2004 Australian dollar values
(AUD$). Income was separated into four bands, roughly
dividing the study households into quartiles: band 1, less
than $52,000 (24% of study households); band 2,
$52,000 to $77,999 (28%); band 3, $78,000 to $103,999
(23%); and band 4, $104,000 or greater (25%). The
approximate proportions for Australian households dur-
ing the same period were: band 1, 54%, band 2, 20%,
band 3, 13%, and band 4, 13% [21].
Parents undertook daily respiratory symptom surveillance
of the study child using a diary card and collected a com-
bined nose-throat swab (NTS) and completed a summary
impact diary when the child had an acute respiratory ill-
ness (ARI). For this study we used a sensitive ARI defini-
tion that had previously been used in an influenza vaccine
efficacy study [22] and our pilot study [23,24]. Symptoms
were classified as category A (fever, wheezing, shortness of
breath, pulmonary congestion or moist cough, pneumo-
nia, or ear infection) and category B (runny nose or nasal
congestion, sore throat, cough, muscle aches, chills, head-
ache, irritability, decreased activity or lethargy or weak-
ness, or vomiting). An ARI of interest required one
category A or two category B symptoms on a single day
[22]. Other than pneumonia, which we asked parents to
record only if supported by a health care professional's
diagnosis, no illness or symptom details, including a
report of otitis media, were validated by study staff or
health care professionals. A new ARI could not commence
unless there were three symptom free days since the end
of the previous ARI. This meant an ARI could contain no
more than two consecutive symptom-free days. Study
families were asked to continue normal healthcare seek-
ing behaviour and treatments, and were not alerted about
the start of the influenza season or asked to alter surveil-
lance during the winter season. Pre-stamped envelopes
were provided and families were asked to return all com-
pleted study documents (daily symptom diary, impact
diaries) at the end of each month. ARI duration was calcu-
lated using symptom diary data and ARIs were classifiedRespiratory Research 2008, 9:11 http://respiratory-research.com/content/9/1/11
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by study staff as being simple (no fever or otitis media
recorded), or occurring with fever, otitis media, or with
both fever and otitis media [22-24].
The NTS was couriered to the Victorian Infectious Dis-
eases Reference Laboratory (VIDRL) where it was tested
for a number of common respiratory viruses using a
polymerase chain reaction (PCR) method for adenovi-
ruses and reverse transcription (RT) PCR for RNA viruses:
influenza A virus, influenza B virus, respiratory syncytial
virus (RSV), parainfluenza viruses I, II, and III (PIVs), and
picornaviruses [19]. A letter outlining these test results
was sent to parents when these details became available.
At completion of the study all specimens were transported
to the Queensland Paediatric Infectious Diseases (Qpid)
Laboratory where they were tested for human metapneu-
movirus (hMPV) and human coronavirus NL63 (hCoV-
NL63) using RT-PCR [19].
Impact diary completion
A summary impact diary was used to collect details of
resources used during the study child's ARI and was based
on an impact diary used in a pilot study [23,24], with
some simplification. The units of resource use requested
were:
▪ health care visits: number and timing of primary care
(general practice) visits, hospital presentations and
admissions, and visits to other providers (such as naturo-
paths, homeopaths);
▪ use of prescribed antibiotics;
▪ laboratory tests performed to investigate the illness;
▪ carer time consumed during the illness seeking health
care; and
▪ excess carer time during the illness spent caring for the ill
child.
We did not collect information about some items that
were shown not to be major cost drivers in the pilot study:
non-antibiotic prescription medication, over-the-counter
and other medication, paid childcare for other children
whilst normal carers were spending time caring for the ill
study subject, and travel costs seeking health care. The
average total cost for these items in the pilot study [23]
was AUD$16 per ARI.
Time values were captured in hours and minutes. Parents
were not given instructions about when or how frequently
they should capture time data during an ARI. For both
carer time spent seeking healthcare and excess time spent
caring for an ill child, time was recorded as a total value
for the ARI in two categories: time away from work and
time away from usual, non-work activities.
Costing methods
All costs were incurred over a 380 day period between 17
January 2003 and 31 January 2004. Costs are reported in
this manuscript using Australian dollar values, with 2003
taken as the reference year for reporting unit prices. The
mean exchange rates for major currencies during the study
were: United Kingdom (UK) pound £1 = AUD$2.49, Euro
€1 = AUD$1.73, and United States (US) $1 = AUD$1.50
[25]. Discounting costs for time preference is not rou-
tinely considered for periods of time less than 12 months,
and as this study period barely exceeds this time frame, no
costs have been discounted.
Details of the source and value for all costs are provided
(Table 1). Applied costs were retrieved, where possible,
from published sources, and where no standard pub-
lished cost was available we used costs derived from the
pilot study. Resource costs were allocated as being borne
by either the 'patient and family' sector, the 'healthcare'
sector, or the 'employer' of absent staff. The proportions
of time away from work seeking healthcare or time away
from work caring for an ill child that were incurred by
either the patient and family sector or met by an employer
were not collected, and these values have been derived
from the same proportions in the pilot study, based on
202 illnesses (Table 1) [23].
We applied a sex-weighted hourly wage rate derived from
the Australian Bureau of Statistics average weekly full-time
adult total earnings for all reported times [26]. We calcu-
lated mean costs (total and by categories) with 95% con-
fidence intervals (95% CI) and median costs with
interquartile ranges for ARIs in study children. Data were
analysed using Stata 9.2 for Windows (StataCorp, Texas,
USA).
Results
There were 234 children, one from each study family, pro-
gressively enrolled in the study and we identified 730 ARIs
in 56,397 child-days of follow-up [19]. Of these, 487 ARIs
(67%) had at least one specimen and an impact diary
available, 41 (6%) had an impact diary returned but no
specimen, 56 (8%) had at least one specimen returned but
no impact diary available, and 146 (20%) had neither a
specimen nor impact diary returned. Children aged
between one and two-years of age contributed the most
person-time to the study (28% of all child-days) and had
the highest acute respiratory illness (ARI) incidence rate
(0.56 ARIs per child-month). Contribution by males and
females was equivalent, and children who attended some
form of out-of-home care were responsible for 67% of all
person-time [19].Respiratory Research 2008, 9:11 http://respiratory-research.com/content/9/1/11
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Table 1: Source, sector distribution, and value of applied costs used in costing calculations for acute respiratory illnesses
Resource item Sector Source of applied cost Applied cost Value
Primary care visits Patient and family Medicare Australia [60,61] Mean patient contribution 
per service by quarter, 
patient and bulk billed 
services from general 
practitioners and 
vocationally registered 
general practitioners
January to March 2003: 
$4.03
April to June 2003: $4.08
July to September 2003: 
$4.34
October to December 
2003: $4.61
January 2004: $4.64
Health Medicare Australia [62,63] 85% (reimbursable 
amount) of code 23, 
Medicare Benefits Schedule
January to October 2003: 
$25.05
November 2003 to January 
2004: $25.70
Specialist visits Patient and family Medicare Australia [60,61] Mean patient contribution 
per specialist visit by 
quarter
January to March 2003: 
$19.30
April to June 2003: $19.56
July to September 2003: 
$19.74
October to December 
2003: $20.36
January 2004: $21.65
Health Medicare Australia [62,63] 85% (reimbursable 
amount) of code 104, 
Medicare Benefits Schedule
January to October 2003: 
$58.95
November 2003 to January 
2004: $60.45
Other health care provider 
visits
Patient and family Pilot study [] Mean other health care 
provider visit cost from 
pilot study, derived from 
10 visits
$15.63 per visit to allied 
and alternative health 
professionals
Hospital emergency 
department visits without 
admission
Health The Australian 
Government Department 
of Health and Ageing []
Australian Ambulatory 
Classes group 23 (other 
respiratory diseases 
without procedure)
$40 per visit
Diagnostic tests 15% Patient and family
85% Health
Medicare Australia [62,63] Medicare Benefits 
Scheduled fee for 
diagnostic tests
January 2003 to January 
2004
$28.35 Chest x-ray (code 
58500)
January to October 2003
$14.20 Full blood 
examination (code 65070)
$16.35 Urea, electrolytes, 
creatinine, liver function 
tests (code 66515)
$17.10 Urine microscopy, 
culture, identification, and 
sensitivity (code 69333)
November 2003 to January 
2004
$14.65 Full blood 
examination (code 65070)
$16.85 Urea, electrolytes, 
creatinine, liver function 
tests (code 66515)
$17.60 Urine microscopy, 
culture, identification, and 
sensitivity (code 69333)
Antibiotics Patient and family Pilot study [] Mean antibiotic course cost 
from pilot study, derived 
from 42 courses
$13.80 per courseRespiratory Research 2008, 9:11 http://respiratory-research.com/content/9/1/11
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There were five illnesses which involved a hospital admis-
sion, all with an impact diary available. The mean cost of
these five ARIs, including the cost of admission, was
$3,409 (95% CI $2,798 to $4,020). Of the remaining 725
ARIs, the 202 illnesses without an impact diary had a
mean duration of 8.8 days compared with 13.5 days for
ARIs with impact data available; median 6 days versus 11
days. Simple ARIs made up 57% (116/202) of no impact
diary ARIs and 47% (248/523) of ARIs with an impact
diary.
The 523 illnesses with a diary returned that did not
involve a hospital admission had a total cost of $161,454
(Table 2), and mean cost of $309 (95% CI $263 to $354).
As our particular interest is in the cost of community-
managed ARIs, that is, those illnesses that do not require
Time seeking health care 
away from work
61% Patient and family
39% Employer
Australian Bureau of 
Statistics []
Average weekly, full-time 
adult total earnings for 
females and males used to 
provide an hourly rate 
(based on a 38 hour 
working week)
January 2003
Female $21.62 Male $26.67
February to April 2003
Female $21.94 Male $27.10
May to July 2003
Female $22.25 Male $27.51
August to October 2003
Female $22.49 Male $27.81
November 2003 to January 
2004
Female $22.71 Male $28.00
Time seeking health care 
away from usual activity
Patient and family
Excess time caring for ill 
child away from work
31% Patient and family
69% Employer
Excess time caring for ill 
child away from usual 
activity
Patient and family
Hospitalization Health Public hospital admission 
National Hospital Cost 
Data Collection [65,66]
Victorian values for code 
E62C (Respiratory 
infection/inflammation 
without complication or 
co-morbidity)
Round 7 (2002/2003) 
$2,331
Round 8 (2003/2004) 
$2,441
Table 1: Source, sector distribution, and value of applied costs used in costing calculations for acute respiratory illnesses (Continued)
Table 2: Total cost, mean cost (95% confidence interval), and median cost (interquartile range) of acute respiratory illnesses by virus 
identification
Number (%) Total cost Mean cost 95% confidence
interval
Median cost Interquartile range
Influenza A virus 17 (3.3%) $15,366 $904 $89 to $1719 $571 $162, $1023
RSVa 33 (6.3%) $10,047 $304 $194 to $415 $198 $60, $398
Picornaviruses 197 (37.7%) $52,597 $267 $211 to $323 $124 $32, $337
hCoV-NL63b 6 (1.1%) $1,508 $251 -$77 to $580 $83 $30, $625
Adenoviruses 17 (3.3%) $4,212 $248 $140 to $356 $185 $90, $341
PIVsc 21 (4.0%) $4,804 $229 $104 to $354 $112 $84, $291
hMPVd 15 (2.9%) $3,284 $219 $109 to $328 $204 $57, $324
Co-identifications 51 (9.8%) $17,503 $343 $212 to $475 $185 $72, $431
No virus identified 126 (24.1%) $39,853 $316 $208 to $425 $151 $44, $364
No specimen 40 (7.6%) $12,281 $307 $212 to $402 $216 $88, $434
All ARIse 523 (100.0%) $161,454f $309 $263 to $354 $156 $45, $378
a Respiratory syncytial virus.
b Human coronavirus NL63.
c Parainfluenza viruses.
d Human metapneumovirus.
e Acute respiratory illnesses.
f Column total does not equal column sum due to rounding.Respiratory Research 2008, 9:11 http://respiratory-research.com/content/9/1/11
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an admission to hospital, further analyses will include
only these 523 illnesses.
There were 248 simple ARIs (ARIs without fever or otitis
media), with a mean cost of $180 (95% CI $131 to $230).
The 207 ARIs with fever had a mean cost $406 (95% CI
$318 to $494), the 26 ARIs with otitis media had a mean
cost $362 (95% CI $203 to $520), and the 42 ARIs with
fever and otitis media had a mean cost of $553 (95% CI
$395 to $711). By household income band, there were
121 ARIs from the lowest band (ARI incidence rate: 0.35
per child-month) with a mean cost of $222 (95% CI $174
to $270), 144 ARIs from band 2 (0.37 ARIs per child-
month) had a mean cost $375 (95% CI $244 to $506),
110 ARIs from band 3 (0.44 ARIs per child-month) with
mean cost $366 (95% CI $282 to $451), and 148 ARIs
from band 4 (0.43 ARIs per child-month) with mean cost
$272 (95% CI $208 to $337). The mean cost of an ARI in
a female subject was $67 greater than their male counter-
parts: female mean cost $341 (95% CI $265 to $418),
male mean cost $274 (95% CI $228 to $319).
The mean and median costs by virus identification,
including co-identification and specimen availability, are
provided (Table 2). The differences between the mean val-
ues and the median values demonstrate the right-skewed
nature of these data, similar to other health-related costs
[27]. Whilst confidence intervals overlap, the point esti-
mate of the mean cost of an influenza A ARI, $904, is three
times higher than the next most expensive single virus
ARI: RSV $304. Of the 51 ARIs where more than one virus
was identified, influenza A virus was present in four: two
illnesses with co-identification with a picornavirus alone,
one illness with hCoV-NL63 alone, and one illness with a
picornavirus and PIV. These four illnesses had a mean cost
of $499. There were no illnesses where influenza B virus
was identified. Three children had received influenza vac-
cine in the year prior to the study and none had an influ-
enza-positive ARI.
As the difference in mean cost between the most expen-
sive (RSV: $304) and least expensive (hMPV: $219) non-
influenza single virus ARI falls within a comparatively
narrow band ($85) we collapsed these data into a single
category for further comparisons (Table 3). The mean cost
for non-influenza single virus ARIs was $265 (95% CI
$223 to $306). The cost of excess carer time away from a
usual activity averaged $706 per ARI for influenza A, mak-
ing up 78% of the total mean cost of illness, compared
with $164 and 62% for other single virus illnesses.
Of the mean cost for all illnesses, $19 (6%) was met by the
healthcare sector, $245 (79%) by the patient and family
sector, and $45 (15%) was met by employers paying for
an employee who was seeking healthcare for or caring for
an ill child. The equivalent values for influenza A infec-
tions are: $36 (4%), $780 (86%), and $87 (10%), respec-
tively. In influenza A ARIs the key cost driver, carer time
away from usual activity, resulted in a mean loss of two
hours per day per illness. For all other illness categories,
this value ranged from one half to three quarters of an
hour per day per ARI.
There was little difference in the mean duration of influ-
enza A illnesses and other single virus illnesses, but co-
identifications were 2.2 and 3.6 days longer than each of
these respectively (Table 4). The mean delay between ill-
ness onset and a result letter being sent was shortest in
influenza illnesses at 6.3 days (Table 4).
Discussion
In this study we present the costs associated with commu-
nity-managed respiratory viral infections in healthy pre-
school aged children. These costs are based on the direct
recording of impact information captured by parents
when the study child was unwell. The study has a unique
combination of features including a sensitive definition
for ARI, parent-collected specimens, laboratory testing for
respiratory viruses using sensitive molecular methods,
and, based on findings from our pilot study, comprehen-
Table 3: Mean values and mean cost of components of resource use during ARIs
Number 
of ARIs
Primary care visits All other 
healthcare 
costsa
Seeking healthcare time 
off workb
Seeking healthcare time 
away from usual activityb
Excess care time off 
workb
Excess care time away 
from usual activityb
Mean 
number
Mean 
cost
Mean cost Mean 
male 
time
Mean 
female 
time
Mean 
cost
Mean 
male 
time
Mean 
female 
time
Mean 
cost
Mean 
male 
time
Mean 
female 
time
Mean 
cost
Mean 
male 
time
Mean 
female 
time
Mean 
cost
Influenza A virus 17 1.11 $32.85 $12.84 0.00 0.12 $2.65 0.12 0.94 $24.37 1.76 3.38 $125.16 4.29 26.09 $706.00
Other single virus 289 0.57 $16.73 $7.19 0.02 0.55 $12.83 0.04 0.66 $15.64 0.47 1.60 $48.55 1.09 6.01 $163.61
Co-identifications 51 0.76 $22.46 $3.79 0.00 0.38 $8.43 0.03 0.50 $11.90 1.49 2.49 $96.41 1.46 7.18 $200.20
No virus identified 126 0.63 $18.65 $7.07 0.02 0.22 $5.58 0.03 0.67 $15.79 0.88 1.60 $60.23 1.48 7.53 $208.97
No specimen returned 40 0.80 $23.72 $25.70 0.00 0.48 $10.64 0.41 1.26 $39.66 0.69 1.81 $59.31 1.13 5.25 $148.01
All ARIsc 523 0.64 $18.81 $8.43 0.02 0.44 $10.15 0.07 0.70 $17.43 0.73 1.76 $59.34 1.33 7.08 $194.54
a All other healthcare costs is the sum of hospital emergency department presentations, other provider costs (specialists, other therapists), laboratory tests, and prescribed antibiotics.
b All time recorded in hours.
c Acute respiratory illnesses.Respiratory Research 2008, 9:11 http://respiratory-research.com/content/9/1/11
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sive collection of costs, including the previously neglected
indirect cost, time away from a usual, non-work activity.
We found, from a societal perspective, the point estimate
for the mean cost of all ARIs ($309; 95% CI $263 to $354)
was not dissimilar to the mean value we calculated from
the pilot study ($241; 95% CI $191 to $291) [23] using
the same ARI definition and a slightly modified impact
diary. The use of PCR testing for diagnosis on collected
specimens allowed us to assign impact and costs to spe-
cific viral agents. For all but influenza A illnesses, the cost
of community-managed ARIs in healthy preschool-aged
children fell within a relatively narrow $85 range. Despite
overlapping confidence intervals, the finding of most note
in this study was the dramatically higher point estimate of
the mean cost of influenza A ARIs, being three times
higher than illnesses caused by RSV and the other com-
mon respiratory viral infections of childhood. The pres-
ence of fever and/or otitis media generally increased the
mean cost of illness; but despite having a high prevalence
of fever, a longer mean duration, and higher primary care
usage [19], adenoviral infections, for example, did not
have the cost burden of influenza infections. This high-
lights the pivotal contribution of excess carer time away
from usual non-work activity to total costs, making it the
key cost driver for all ARIs in children and differentially
amplifying the total costs of influenza illnesses. Whilst the
confidence intervals for mean cost of influenza A ARIs and
other single virus ARIs overlap, due to the relatively small
number of influenza illnesses available for costing, we
believe it is unlikely that chance could account for such an
extreme difference.
The availability of preventive vaccines and specific thera-
peutic options makes influenza the most studied of respi-
ratory viruses in all age groups; no other virus is more
predictably disruptive year-on-year than annual interpan-
demic influenza [2-5]. Studies conducted in the second
half of last century [28-31] and recent observation [32,33]
and intervention [34-36] studies show children have com-
paratively higher rates of influenza infection and are the
most important transmitters of infection within house-
holds and communities. Whilst dollar amounts may not
directly translate, impact data from this study may be
transferable to other countries with developed economies,
and similar disease epidemiology and healthcare systems.
Ideally further studies in other countries should be con-
ducted to allow for an examination of how impact and
cost data vary with the nature of the healthcare system,
local virus epidemiology, and other societal factors,
including household structure.
Despite lower mean costs than influenza illnesses and the
lack of population-based prevention options, the impor-
tance of working towards the prevention of other respira-
tory viral infections is obvious. Picornavirus ARIs, though
typically milder and more difficult to be certain of a causal
association with illness [37,38], were associated with the
highest overall costs of any viral group totalling over
$50,000 or one-third of all costs, for the 12-month study
period. In the absence of specific vaccines and therapies
for other viruses, the application of nonpharmaceutical
interventions at a population level, such as improved
hand and respiratory hygiene, may have an important
place in reducing illness due to respiratory viruses [16].
Our findings reinforce the importance of virus testing in
such studies to accurately estimate epidemiology and
costs [11]. These data add to accumulating evidence that
laboratory confirmation of influenza, in particular, is
required, rather than less specific influenza-like illness
(ILI) definitions or hospital coding. Other recent studies
have found laboratory-confirmed influenza hospitaliza-
tions were two to four times more costly [39-41] than
shown in previous studies using coding-based estimates
[6,42-44]. When ILI definitions or coding are used, rather
than laboratory confirmation, a lack of specificity results
in influenza illnesses being mixed with other agents,
thereby considerably diluting cost differences [45,46]. A
direct comparison of parent-collected NTS specimens
with collection of a more invasive specimen, such as a
nasopharyngeal aspirate, by a healthcare worker at the
time of an ARI was beyond the scope of this study. Any
reduction in sensitivity caused by the type of specimen
used is likely to minor: our finding that 74% of all speci-
mens collected from children in this study were positive
for at least one virus is within the range of values from
recent home visit studies which also used PCR for diagno-
sis and nasopharyngeal aspirates (69%) [47] or nasal lav-
ages (83%) [48].
There are clearly some issues about the cost of illnesses
caused by respiratory viruses in children unresolved by
our study, and some issues that need to be considered
before interpretation. Despite being a relatively large
cohort the number of illnesses on which to make costing
estimates for some virus types is quite small. Further com-
munity-based estimates are required to not only confirm
our findings but to improve precision around point
estimates.
Compared with the Australian population, households
with lower incomes were under-represented in our study
sample, and, despite overlapping confidence intervals
around income band point estimates of mean costs, this
may have lead to an overestimation of total costs. How-
ever, this may be balanced somewhat by the over-repre-
sentation of households from the top income band which
had a relatively lower mean ARI cost ($272). This pattern
of household income distribution was similar to thatRespiratory Research 2008, 9:11 http://respiratory-research.com/content/9/1/11
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found in the pilot study [23]. For this study we sought to
make our study sample more representative of the general
community by focusing our recruitment efforts in local
council areas with a higher proportion of lower income
households. We have no empiric data available that
would allow us to quantify the effect of any potential bias
resulting from this skewed sample. Other recent burden
studies do not report similar household level income data
to allow for comparison [49-51]. It may be the case that
lower income households are under-represented as they
do not have the spare capacity required, in time or other
resources, to allow for study involvement.
We received impact diaries for just over 70% of all ARIs
identified by daily symptom surveillance. ARIs without a
diary were more likely to be shorter and without fever or
otitis media; any information bias resulting from this
would likely be in the direction of inflating mean illness
costs. Our study only captured information from a single
season with higher than normal influenza activity with
H3N2 influenza A (drifted strain subtype A/Fujian/411/
2002-like) being the predominant circulating type [52].
Variations in incidence and severity year-by-year for all
respiratory viruses make it difficult to directly translate
our findings to other years.
We believe documenting all time spent on caring for an ill
child is important, even when taken away from a usual
activity. We appreciate that applying standard wage rates
to leisure time is not a straightforward issue in economics.
This approach values carer leisure time and non-paid
working time in a similar way to a worker's time consist-
ent with neoclassical theories of labour economics [53].
In attaching value to leisure time and using sex-weighted
wage rates, we have made our assumptions explicit, and
provided sufficient detail (Table 3) so that others can
adjust unit prices using different approaches. Previous
burden data [49] have been used to assess the cost-effec-
tiveness (C/E) of using influenza vaccine in children [54].
If our cost values, incorporating these indirect costs, were
used in the numerator of C/E calculations, there is a dis-
tinct possibility of double counting [55]. Double count-
ing is likely where the denominator is a utility measure
that incorporates a quality assessment (such as the quality
adjusted life year or QALY), and most economists would
see leisure time as a logical component of the QALY. There
is also debate [53] about the inclusion, measurement, and
valuation of lost working time in economic evaluations,
with the debate centring on whether in practice QALY
instruments capture income effects related to
absenteeism.
For all illnesses where a specimen was tested, parents
received a result letter by mail. The delay between illness
onset and posting the letter was shortest for influenza ill-
nesses, but for most illnesses parents would have been
aware of the result before illness end. Pandemic influenza
was not being widely discussed in Australia during 2003,
but interpandemic influenza does receive media coverage
annually encouraging vaccine uptake, and this may have
caused parents to overestimate key parameters associated
with their child's influenza-positive illness. However, if
such a bias was in operation it might also be expected that
time values for illnesses where no virus was identified may
be relatively understated when compared to ARIs with
one or more viruses present. We did not find such a phe-
nomenon; ARIs with no virus identified had a higher
mean cost than those with a single virus present, and for
the key cost driver of excess carer time away from a usual
activity, no cause illnesses had higher values than both
single and multiple virus ARIs.
Despite the impact of respiratory viral infections in chil-
dren there are relatively few burden comparisons availa-
ble that collect primary data from ill children. An Italian
study examining the impact of hMPV, RSV, and influenza
in children less than 15-years of age presenting to an
emergency department found hMPV illnesses to be signif-
icantly more burdensome than RSV, having a similar
impact to influenza [50]. In our study hMPV was the least
expensive single-virus illness. This finding may be due to
the different nature of illnesses that result in hospital pres-
entation or hospital admission, compared with commu-
nity managed illness. Of the 730 ARIs in this study only
4.0% (n = 29) prompted hospital presentation, with less
than 1% (n = 5) requiring admission. An excellent com-
munity-based Finnish study describing the burden of
influenza in children 13-years of age or younger over two
seasons, with 2231 child-seasons of data, also contrasts
this imbalance between community-managed and hospi-
talized cases of influenza, with only three emergency
department referrals and one hospital admission in 131
children less than three years of age with influenza [49].
This study differed from ours in that whilst it used labora-
tory confirmation, it did not employ more sensitive
Table 4: Mean duration of ARI and mean delay for result letter
Mean
duration
(days)
Mean delay from
ARIa onset to
results letter
being sent (days)
Influenza A virus 15.2 6.3
Other single virus 13.8 8.9
Co-identifications 17.4 8.8
No virus identified 12.2 8.4
No specimen returned 10.5 --
All ARIsa,b 13.5 8.7
a Acute respiratory illnesses.
b Includes all ARIs with a specimen returned.Respiratory Research 2008, 9:11 http://respiratory-research.com/content/9/1/11
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molecular diagnostics [56], families were required to visit
the study clinic when the study child had fever or signs of
respiratory infection, indirect costs did not include non-
work time away from a usual activity, and the study did
not provide a comparison with other viral acute respira-
tory illnesses [49]. The findings from the Finnish study
reinforce the need to follow children for ARIs over more
than one season, with different rates of influenza infec-
tion from year-to-year in each age group. These differences
extended to changes in likelihood of infection between
age groups: for example, the rate of laboratory-confirmed
influenza increased by one-third from season one (2000–
2001) to season two (2001–2002) for children less than
three years of age, but the rates for three to six year olds
and seven to 13 year olds fell 47% and 86%, respectively.
A German study, recruiting children less than three years
of age with lower respiratory tract infection (LRTI)
through office and hospital-based paediatricians, col-
lected cost of illness from a societal perspective, including
loss of work days by caregivers [51]. This study showed
that non-hospitalized cases of influenza LRTI had twice
the cost of PIV LRTI and were one-third more costly than
RSV LRTI, with this difference made up entirely by indirect
costs [51].
Whilst methods vary, previous cost effectiveness studies of
influenza vaccine in children are characterised by two
findings: first, that cost-effectiveness is unsurprisingly
enhanced by taking a societal perspective through the
inclusion of indirect costs [5,6,8,43,54,57]. Our findings
reinforce the importance of indirect costs [51], and high-
light a previously inadequately measured layer of burden
– carer time away from a usual, non-work activity. Second,
the potential cost-effectiveness of implementing a vacci-
nation program is improved by flexible or non-individual
based delivery programs [6,43]. Vaccine delivered
through pharmacies for a small service fee – improving
access and negating the time and costs associated with a
primary care visit – or large school-based programs, are
likely to be acceptable to parents and providers. It is likely
that the cost benefits of preventing influenza in children
would extend beyond the targeted age-group [58], similar
to the indirect effects in older age groups seen following
the introduction of childhood conjugate pneumococcal
vaccination in the US [59].
Conclusion
Our study reinforces the costly impact of all respiratory
viruses, but particularly interpandemic influenza, on chil-
dren, their families, and society. Efforts to further explore
the costs associated with community-managed illness
over a number of seasons for all respiratory infections are
needed. Similar to recent hospital-based findings, using
laboratory-confirmation to specifically identify influenza
appears to increase the cost of illness many fold; a finding
that may make population-based vaccination programs a
more cost-effective proposition.
We believe the use of parent-collected specimens may
have important effects in reducing bias in both the epide-
miologic and impact data collected. Not requiring parents
to either present with their ill child to a health clinic or
host a home visit by study staff may result in enhanced
ARI surveillance, but more importantly, allows for the
reporting of impact data uncontaminated by compliance
with study procedures, thereby reducing any impact a
Hawthorne effect may have. Further studies that collect
primary, integrated epidemiologic and economic data,
particularly indirect costs, directly from families about
community-managed ARIs in children, are required. Such
data would allow for a more informed exploration of the
cost-effectiveness of vaccine programs and other interven-
tions designed to reduce the morbidity associated with
ARIs in children.
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